Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher dose will move forward. What does this update mean for the HD community and this trial?
A new CRISPR-based technology, called RIDE, is a leap forward for this trail-blazing technology. With the precision of a scalpel sharp enough to rewrite the very code of life, researchers have used it with the hope of treating Huntington’s disease.
The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what 2025 has in store for the Huntington's disease community
As we begin 2025, we look back on all of the Huntington’s disease research news and progress the field has made in the last 12 months.
Vico Therapeutics have shared interim data about their drug, VO659, which targets the CAG expansion that causes several genetic diseases, including #Huntingtonsdisease and #spinocerebellarataxia
A new Phase 1 clinical trial for the huntingtin-lowering drug ALN-HTT02 was initiated this week with the first dose given. Read on to learn details about the trial and how it compares to other ongoing huntingtin-lowering trials in the clinic.
uniQure ushered in the end of the year by releasing some promising data from their huntingtin-lowering gene therapy trials
More good news for the HD community from uniQure, whose one-and-done gene therapy appears safe and shows hints of slowing down signs and symptoms of the disease
There’s more good news in the forecast in the Huntington’s disease therapeutic space as we receive positive results from Skyhawk Therapeutics about their small molecule SKY-0515 that lowers huntingtin and targets somatic expansion.